Day One Biopharmaceuticals Set to Release Q4 Earnings on February 24
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 23 2026
0mins
Should l Buy DAWN?
Source: seekingalpha
- Earnings Announcement: Day One Biopharmaceuticals (DAWN) is set to announce its Q4 2023 earnings on February 24 after market close, with consensus EPS estimate at -$0.15 and revenue expected at $48.85 million, highlighting market interest in the company's financial performance.
- Upward Revisions: Over the last three months, both EPS and revenue estimates have seen four upward revisions with no downward adjustments, indicating increased analyst confidence in the company's future performance, which could positively impact stock prices.
- Future Revenue Projections: Day One projects U.S. net product revenue for OJEMDA to be between $225 million and $250 million in 2026, reflecting the company's optimistic outlook on market potential, which may attract more investor interest.
- Positive Market Reaction: Ahead of the earnings release, Day One's stock has surged, indicating market optimism regarding the company's prospects, especially with the upcoming J.P. Morgan Healthcare Conference where investor expectations are high.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DAWN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DAWN
Wall Street analysts forecast DAWN stock price to rise
9 Analyst Rating
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 10.600
Low
16.00
Averages
22.29
High
29.00
Current: 10.600
Low
16.00
Averages
22.29
High
29.00
About DAWN
Day One Biopharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing targeted therapies for people of all ages with life-threatening diseases. It partners with clinical oncologists, families, and scientists to identify, acquire, and develop cancer treatments. Its commercial product, OJEMDA (tovorafenib), is an oral, brain-penetrant, selective type II rapidly accelerated fibrosarcoma (RAF) kinase inhibitor. OJEMDA is used for the treatment of patients over six months of age and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. Its pipeline product candidates include DAY301 and Emi-Le (emiltatug ledadotin). DAY301 is a novel Antibody Drug Conjugate, or ADC, targeting protein-tyrosine kinase 7, or PTK7. Emi-Le (emiltatug ledadotin) is a novel antibody drug conjugate (ADC) targeting the B7-H4 protein in clinical development to treat the rare cancer adenoid cystic carcinoma (ACC).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Day One Biopharmaceuticals Reports Q4 and Full-Year 2025 Financial Results
- Improved Financial Performance: Day One Biopharmaceuticals reported a reduced net loss of $21.3 million for Q4 2025, down from $65.7 million the previous year, indicating effective cost management and revenue growth strategies.
- Product Revenue Surge: OJEMDA net product revenues reached $52.8 million in Q4 2025, an 82.8% increase from $29 million in the prior year, reflecting strong market demand and enhancing the company's revenue base.
- Optimistic Future Outlook: The company anticipates U.S. OJEMDA net product revenue to range between $225 million and $250 million in 2026, demonstrating management's confidence in future sales growth, which may attract more investor interest.
- Strong Cash Reserves: As of December 31, 2025, the company had $441.1 million in cash and short-term investments, providing financial flexibility for R&D and market expansion, supporting future clinical trials and product development.
See More
Day One Biopharmaceuticals Reports Strong Q4 2025 Earnings and Growth Outlook
- Significant Revenue Growth: Day One Biopharmaceuticals reported net product revenue of $155.4 million for 2025, marking a 172% year-over-year increase, demonstrating strong commercial performance, with 2026 revenue guidance set between $225 million and $250 million, reinforcing market position.
- Improved Product Persistence: In Q4, prescriptions for OJEMDA exceeded 1,300, reflecting an 11% quarter-over-quarter growth, while the median duration of therapy is trending towards 19 months, indicating positive progress in driving new patient starts and optimizing treatment persistence.
- Strong Financial Foundation: The company ended 2025 with approximately $441 million in net cash and no debt, providing robust financial support for future commercial growth and pipeline advancement, showcasing the scalability of its operating model.
- Global Expansion Strategy: Management emphasized the partnership with Ipsen for ex-U.S. regulatory approvals and the completion of the Mersana acquisition, which enriches the product pipeline and is expected to drive future international market expansion and clinical milestone achievements.
See More
Day One Biopharmaceuticals Reports Q4 2025 Earnings Highlights
- Revenue Beat: Day One Biopharmaceuticals reported Q4 2025 revenue of $52.8 million, exceeding expectations by $2.99 million, indicating strong product sales performance that is likely to boost future market confidence.
- Reduced Net Loss: The net loss for Q4 2025 was $21.3 million, significantly down from $65.7 million in Q4 2024, suggesting improvements in cost control and operational efficiency, which may enhance investor perceptions of the company's financial health.
- Strong Cash Position: As of December 31, 2025, the company had $441.1 million in cash, cash equivalents, and short-term investments, ensuring sufficient funding for future R&D and market expansion, thereby strengthening its operational sustainability.
- Optimistic Outlook: Day One projects 2026 U.S. net product revenue for OJEMDA between $225 million and $250 million, reflecting confidence in future product market performance, which may attract more investor interest in its long-term growth potential.
See More
Day One Biopharmaceuticals Reports Strong 2025 Financial Results and Growth Outlook
- Revenue Growth: In 2025, Day One's OJEMDA net product revenue reached $155.4 million, reflecting a 172% year-over-year increase, indicating strong market demand and widespread adoption by prescribers, with guidance for 2026 projected between $225 million and $250 million.
- Clinical Trial Progress: Three-year data from the FIREFLY-1 trial was presented at the 2025 Society for Neuro-Oncology Annual Meeting, confirming the long-term safety and efficacy of OJEMDA in patients with relapsed or refractory pLGG, thereby enhancing the company's market position in rare cancers.
- R&D Expense Management: Research and development expenses totaled $148.1 million in 2025, significantly down from 2024, demonstrating the company's ability to control costs while still advancing product development and improving overall financial health.
- Strong Cash Position: As of December 31, 2025, Day One reported cash and short-term investments totaling $441.1 million, ensuring sufficient funding for future R&D and market expansion initiatives.
See More
Day One Biopharmaceuticals Set to Release Q4 Earnings on February 24
- Earnings Announcement: Day One Biopharmaceuticals (DAWN) is set to announce its Q4 2023 earnings on February 24 after market close, with consensus EPS estimate at -$0.15 and revenue expected at $48.85 million, highlighting market interest in the company's financial performance.
- Upward Revisions: Over the last three months, both EPS and revenue estimates have seen four upward revisions with no downward adjustments, indicating increased analyst confidence in the company's future performance, which could positively impact stock prices.
- Future Revenue Projections: Day One projects U.S. net product revenue for OJEMDA to be between $225 million and $250 million in 2026, reflecting the company's optimistic outlook on market potential, which may attract more investor interest.
- Positive Market Reaction: Ahead of the earnings release, Day One's stock has surged, indicating market optimism regarding the company's prospects, especially with the upcoming J.P. Morgan Healthcare Conference where investor expectations are high.
See More
AIGH Capital Fully Exits Lumen Technologies Stake
- Complete Exit: On February 2, 2026, AIGH Capital Management LLC reported a full exit from its Lumen Technologies stake, selling 2.55 million shares for an estimated $15.61 million, indicating potential concerns about Lumen's future amidst ongoing transformation challenges.
- Stock Performance: As of February 1, 2026, Lumen's stock was priced at $8.82, reflecting a 78.5% increase over the past year, significantly outperforming the S&P 500 by 64.2 percentage points, suggesting market optimism about its strategic pivot despite underlying debt issues.
- Strategic Business Shift: Following the $5.75 billion sale of its mass market fiber business to AT&T, Lumen aims to reinvest in new infrastructure, although the costly nature of this transformation raises questions about its long-term profitability and market positioning.
- Debt Burden Concerns: With over $17.6 billion in long-term debt reported in Q3 2025, Lumen faces significant financial challenges, and while the divestiture may alleviate some pressure, the company's ongoing transformation could complicate its recovery and stock performance outlook.
See More
Day One Biopharmaceuticals Reports Q4 and Full-Year 2025 Financial Results
- Improved Financial Performance: Day One Biopharmaceuticals reported a reduced net loss of $21.3 million for Q4 2025, down from $65.7 million the previous year, indicating effective cost management and revenue growth strategies.
- Product Revenue Surge: OJEMDA net product revenues reached $52.8 million in Q4 2025, an 82.8% increase from $29 million in the prior year, reflecting strong market demand and enhancing the company's revenue base.
- Optimistic Future Outlook: The company anticipates U.S. OJEMDA net product revenue to range between $225 million and $250 million in 2026, demonstrating management's confidence in future sales growth, which may attract more investor interest.
- Strong Cash Reserves: As of December 31, 2025, the company had $441.1 million in cash and short-term investments, providing financial flexibility for R&D and market expansion, supporting future clinical trials and product development.
See More
Day One Biopharmaceuticals Reports Strong Q4 2025 Earnings and Growth Outlook
- Significant Revenue Growth: Day One Biopharmaceuticals reported net product revenue of $155.4 million for 2025, marking a 172% year-over-year increase, demonstrating strong commercial performance, with 2026 revenue guidance set between $225 million and $250 million, reinforcing market position.
- Improved Product Persistence: In Q4, prescriptions for OJEMDA exceeded 1,300, reflecting an 11% quarter-over-quarter growth, while the median duration of therapy is trending towards 19 months, indicating positive progress in driving new patient starts and optimizing treatment persistence.
- Strong Financial Foundation: The company ended 2025 with approximately $441 million in net cash and no debt, providing robust financial support for future commercial growth and pipeline advancement, showcasing the scalability of its operating model.
- Global Expansion Strategy: Management emphasized the partnership with Ipsen for ex-U.S. regulatory approvals and the completion of the Mersana acquisition, which enriches the product pipeline and is expected to drive future international market expansion and clinical milestone achievements.
See More
Day One Biopharmaceuticals Reports Q4 2025 Earnings Highlights
- Revenue Beat: Day One Biopharmaceuticals reported Q4 2025 revenue of $52.8 million, exceeding expectations by $2.99 million, indicating strong product sales performance that is likely to boost future market confidence.
- Reduced Net Loss: The net loss for Q4 2025 was $21.3 million, significantly down from $65.7 million in Q4 2024, suggesting improvements in cost control and operational efficiency, which may enhance investor perceptions of the company's financial health.
- Strong Cash Position: As of December 31, 2025, the company had $441.1 million in cash, cash equivalents, and short-term investments, ensuring sufficient funding for future R&D and market expansion, thereby strengthening its operational sustainability.
- Optimistic Outlook: Day One projects 2026 U.S. net product revenue for OJEMDA between $225 million and $250 million, reflecting confidence in future product market performance, which may attract more investor interest in its long-term growth potential.
See More
Day One Biopharmaceuticals Reports Strong 2025 Financial Results and Growth Outlook
- Revenue Growth: In 2025, Day One's OJEMDA net product revenue reached $155.4 million, reflecting a 172% year-over-year increase, indicating strong market demand and widespread adoption by prescribers, with guidance for 2026 projected between $225 million and $250 million.
- Clinical Trial Progress: Three-year data from the FIREFLY-1 trial was presented at the 2025 Society for Neuro-Oncology Annual Meeting, confirming the long-term safety and efficacy of OJEMDA in patients with relapsed or refractory pLGG, thereby enhancing the company's market position in rare cancers.
- R&D Expense Management: Research and development expenses totaled $148.1 million in 2025, significantly down from 2024, demonstrating the company's ability to control costs while still advancing product development and improving overall financial health.
- Strong Cash Position: As of December 31, 2025, Day One reported cash and short-term investments totaling $441.1 million, ensuring sufficient funding for future R&D and market expansion initiatives.
See More
Day One Biopharmaceuticals Set to Release Q4 Earnings on February 24
- Earnings Announcement: Day One Biopharmaceuticals (DAWN) is set to announce its Q4 2023 earnings on February 24 after market close, with consensus EPS estimate at -$0.15 and revenue expected at $48.85 million, highlighting market interest in the company's financial performance.
- Upward Revisions: Over the last three months, both EPS and revenue estimates have seen four upward revisions with no downward adjustments, indicating increased analyst confidence in the company's future performance, which could positively impact stock prices.
- Future Revenue Projections: Day One projects U.S. net product revenue for OJEMDA to be between $225 million and $250 million in 2026, reflecting the company's optimistic outlook on market potential, which may attract more investor interest.
- Positive Market Reaction: Ahead of the earnings release, Day One's stock has surged, indicating market optimism regarding the company's prospects, especially with the upcoming J.P. Morgan Healthcare Conference where investor expectations are high.
See More
AIGH Capital Fully Exits Lumen Technologies Stake
- Complete Exit: On February 2, 2026, AIGH Capital Management LLC reported a full exit from its Lumen Technologies stake, selling 2.55 million shares for an estimated $15.61 million, indicating potential concerns about Lumen's future amidst ongoing transformation challenges.
- Stock Performance: As of February 1, 2026, Lumen's stock was priced at $8.82, reflecting a 78.5% increase over the past year, significantly outperforming the S&P 500 by 64.2 percentage points, suggesting market optimism about its strategic pivot despite underlying debt issues.
- Strategic Business Shift: Following the $5.75 billion sale of its mass market fiber business to AT&T, Lumen aims to reinvest in new infrastructure, although the costly nature of this transformation raises questions about its long-term profitability and market positioning.
- Debt Burden Concerns: With over $17.6 billion in long-term debt reported in Q3 2025, Lumen faces significant financial challenges, and while the divestiture may alleviate some pressure, the company's ongoing transformation could complicate its recovery and stock performance outlook.
See More
